FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W178953162> ?p ?o ?g. }

• W178953162 abstract "DNA vaccines against cancer have shown promising results in animal models. Efficient antigen-specific T cell responses and tumor protection have been demonstrated after vaccination with DNA encoding tumor antigens in mice. Phase I clinical trials have furthermore demonstrated that repetitive DNA vaccinations in humans are well tolerated, and that tumor antigen-specific immune responses can be induced. However, it stands clear that new adjuvants and/or delivery systems need to be explored to enhance the anti-tumor immune responses activated by DNA vaccines in humans. The aim of the studies in this thesis was to investigate different adjuvants and delivery methods for a DNA vaccine against prostate cancer (PC). PC is the most commonly diagnosed cancer in Swedish men (~ 9000 new cases/year), and the fourth leading cause of cancer-related deaths in the developed countries worldwide. Current treatments are debilitating and only available for localized disease. For men with hormone-refractory PC there is no curative treatment and the prognosis is extremely poor. Therefore, there is an urgent need for new treatment strategies. The development of immunotherapeutic vaccination protocols against PC, based on the induction of autoimmunity to prostate tissues, is attractive since the prostate is not a vital organ beyond the reproductive years. The DNA vaccine used in these studies encodes prostate-specific antigen (PSA), a protein expressed almost exclusively by normal prostate epithelial cells and PC cells. The first study of our PSA/DNA vaccine demonstrated that PSA-specific cytotoxic T lymphocytes could be induced in mice. When two cytokine adjuvants, granulocyte macrophage-colony stimulating factor (GM-CSF) and interleukin-2 (IL-2), were co-delivered with the DNA vaccine, 80 % of the mice were protected against a syngenic challenge with PSA-expressing tumor cells. Next the safety, feasibility, and biological efficacy of the PSA/DNA vaccine was evaluated in a phase I clinical trial in patients with hormonerefractory PC. The DNA vaccine was delivered in doses of 100, 300 or 900 μg together with the cytokines GM-CSF and IL-2, during five cycles with monthly intervals. No adverse effects (WHO grade >2) were observed in any patients. PSA-specific cellular responses and an increase in anti-PSA antibodies were detected in two of three patients after vaccination with the highest vaccine dose. This proved an important proof of principle, namely that tolerance to PSA in PC patients could be overcome by vaccination with PSA/DNA. The clinical study furthermore made clear that DNA vaccination must induce more effective immune responses to have an impact on survival of PC patients. To further improve PSA-specific immune responses induced by the PSA/DNA vaccine we investigated a new delivery method, in vivo electroporation (EP). When injecting the DNA vaccine intradermally and applying a short sequence (~ 3 sec) of optimized electrical pulses, the number of induced PSA-specific CD8 T cells was greatly increased. The amount of DNA necessary to induce PSA-specific T cells could be reduced by 80 % when the DNA was delivered intradermally with EP, compared to non-electroporative delivery in muscle. In preparation for a second clinical trial, where a xenogenic DNA vaccine encoding rhesus PSA will be delivered intradermally in combination with EP, an amino acid substitution in rhesus PSA creating a naturally processed and presented epitope with high HLA affinity was identified. As PSA/DNA encoding this modified epitope induces PSAspecific T cells in all human and murine T cell cultures tested, we believe that this epitope will facilitate the monitoring of vaccine efficacy in PSA/DNA vaccinated cancer patients." @default.
• W178953162 created "2016-06-24" @default.
• W178953162 creator A5054584357 @default.
• W178953162 date "2006-10-06" @default.
• W178953162 modified "2023-09-24" @default.
• W178953162 title "Delivery of DNA vaccines against cancer" @default.
• W178953162 cites W113716995 @default.
• W178953162 cites W118284139 @default.
• W178953162 cites W1490324405 @default.
• W178953162 cites W1490590930 @default.
• W178953162 cites W1497563480 @default.
• W178953162 cites W1505248622 @default.
• W178953162 cites W1509305962 @default.
• W178953162 cites W1512065983 @default.
• W178953162 cites W1514540900 @default.
• W178953162 cites W1519513582 @default.
• W178953162 cites W1521418395 @default.
• W178953162 cites W1536249747 @default.
• W178953162 cites W1538844879 @default.
• W178953162 cites W1542198162 @default.
• W178953162 cites W1543460784 @default.
• W178953162 cites W1566505170 @default.
• W178953162 cites W1588713113 @default.
• W178953162 cites W1594950156 @default.
• W178953162 cites W1596938308 @default.
• W178953162 cites W1603510059 @default.
• W178953162 cites W1611151946 @default.
• W178953162 cites W1653792548 @default.
• W178953162 cites W1671935408 @default.
• W178953162 cites W1754190360 @default.
• W178953162 cites W1774815589 @default.
• W178953162 cites W1826114831 @default.
• W178953162 cites W1847190381 @default.
• W178953162 cites W1850598717 @default.
• W178953162 cites W1858509526 @default.
• W178953162 cites W1898098760 @default.
• W178953162 cites W1899637912 @default.
• W178953162 cites W1903486456 @default.
• W178953162 cites W1920268203 @default.
• W178953162 cites W1930403058 @default.
• W178953162 cites W1955476223 @default.
• W178953162 cites W1963551591 @default.
• W178953162 cites W1963592300 @default.
• W178953162 cites W1963836672 @default.
• W178953162 cites W1964548837 @default.
• W178953162 cites W1964906479 @default.
• W178953162 cites W1966711839 @default.
• W178953162 cites W1969061981 @default.
• W178953162 cites W1970013976 @default.
• W178953162 cites W1970193565 @default.
• W178953162 cites W1971244095 @default.
• W178953162 cites W1972278895 @default.
• W178953162 cites W1972776485 @default.
• W178953162 cites W1972776583 @default.
• W178953162 cites W1973029003 @default.
• W178953162 cites W1973081965 @default.
• W178953162 cites W1974565005 @default.
• W178953162 cites W1976803149 @default.
• W178953162 cites W1978542226 @default.
• W178953162 cites W1978760190 @default.
• W178953162 cites W1981552834 @default.
• W178953162 cites W1981831700 @default.
• W178953162 cites W1982014262 @default.
• W178953162 cites W1982753930 @default.
• W178953162 cites W1983062261 @default.
• W178953162 cites W1983098174 @default.
• W178953162 cites W1987415831 @default.
• W178953162 cites W1987689247 @default.
• W178953162 cites W1987736203 @default.
• W178953162 cites W1989819045 @default.
• W178953162 cites W1990843557 @default.
• W178953162 cites W1992344690 @default.
• W178953162 cites W1994946971 @default.
• W178953162 cites W1997514744 @default.
• W178953162 cites W1999625461 @default.
• W178953162 cites W2001778929 @default.
• W178953162 cites W2001889320 @default.
• W178953162 cites W2001974402 @default.
• W178953162 cites W2002022916 @default.
• W178953162 cites W2002657509 @default.
• W178953162 cites W2004952803 @default.
• W178953162 cites W2005634587 @default.
• W178953162 cites W2005905399 @default.
• W178953162 cites W2005953810 @default.
• W178953162 cites W2007219316 @default.
• W178953162 cites W2008271960 @default.
• W178953162 cites W2009144057 @default.
• W178953162 cites W2009644962 @default.
• W178953162 cites W2010457947 @default.
• W178953162 cites W2013616623 @default.
• W178953162 cites W2014488064 @default.
• W178953162 cites W2014495927 @default.
• W178953162 cites W2014669469 @default.
• W178953162 cites W2015562865 @default.
• W178953162 cites W2015906116 @default.
• W178953162 cites W2016110802 @default.
• W178953162 cites W2016252953 @default.
• W178953162 cites W2018721303 @default.
• W178953162 cites W2018744718 @default.
• W178953162 cites W2020324589 @default.

• next